SM
IONS icon

Sabby Management’s Ionis Pharmaceuticals IONS Stock Holding History

Sabby Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-428
Closed -$1.92M – 178
2021
Q1 		$1.92M Hold
428
– – 0.37% 53
2020
Q4 		$2.42M Hold
428
– – 0.46% 33
2020
Q3 		$2.03M Buy
428
+304
+245% +$16.9K 0.3% 48
2020
Q2 		$731K Buy
+124
New +$6.9K 0.15% 54
2020
Q1 		– Sell
-2,961
Closed -$17.9M – 96
2019
Q4 		$17.9M Sell
2,961
-77
-3% -$4.59K 4.96% 5
2019
Q3 		$18.2M Buy
3,038
+267
+10% +$17.4K 9.81% 5
2019
Q2 		$17.8M Buy
2,771
+923
+50% +$65.2K 22.39% 1
2019
Q1 		$1.23M Buy
+1,848
New +$119K 0.59% 19
2018
Q1 		– Sell
-1,429
Closed -$7.19M – 169
2017
Q4 		$7.19M Buy
1,429
+6
+0.4% +$329 0.65% 30
2017
Q3 		$7.21M Buy
1,423
+130
+10% +$6.81K 0.47% 29
2017
Q2 		$6.58M Sell
1,293
-18
-1% -$838 0.43% 33
2017
Q1 		$5.27M Buy
1,311
+257
+24% +$11.5K 0.28% 48
2016
Q4 		$5.04M Sell
1,054
-1,117
-51% -$44.2K 0.29% 52
2016
Q3 		$7.96M Sell
2,171
-1,429
-40% -$44.7K 0.3% 51
2016
Q2 		$8.38M Buy
+3,600
New +$116K 0.44% 40
2016
Q1 		– Sell
-1,159
Closed -$7.18M – 322
2015
Q4 		$7.18M Hold
1,159
– – 0.39% 44
2015
Q3 		$4.68M Hold
1,159
– – 0.19% 90
2015
Q2 		$6.67M Sell
1,159
-638
-36% -$40.6K 0.24% 77
2015
Q1 		$11.4M Buy
1,797
+588
+49% +$39.9K 0.48% 41
2014
Q4 		$7.46K Buy
1,209
+829
+218% +$40.9K 0.24% 56
2014
Q3 		$1.48K Buy
+380
New +$13.5K 0.06% 136
2014
Q2 		– Sell
-1,584
Closed -$6.84M – 274
2014
Q1 		$6.84M Buy
1,584
+1,454
+1,118% +$70.5K 0.38% 53
2013
Q4 		$518K Hold
130
– – 0.03% 150
2013
Q3 		$488K Sell
130
-880
-87% -$26.3K 0.03% 156
2013
Q2 		$2.71M Buy
+1,010
New +$21.5K 0.18% 86

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Sabby Management's IONS Position: Q4 2021 in Review

Sabby Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2021, closing a stake of 84,600 shares — an estimated $2.84M sold.

Sabby Management first reported a position in IONS in Q3 2013 and held it in 7 quarters. The position peaked at $4.65M in Q1 2017. 340 funds tracked by Wall St. Rank hold IONS as of Q4 2021.

  • Sabby Management reported no remaining Ionis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sabby Management sold 84,600 Ionis Pharmaceuticals shares in Q4 2021, an estimated $2.84M.
  • Sabby Management first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Sabby Management's Ionis Pharmaceuticals position peaked at $4.65M in Q1 2017.
  • 340 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.